SGLT2 inhibitors decrease mortality and morbidity in patients with heart failure notwithstanding their phenotype and are generally considered safe regardless of the etiology and these benefits are expected early in the course of treatment, often as early as within 8-10 months [19,20]. The gene discussed is SLC5A2; the disease is heart failure.